Log in

NASDAQ:OPHT - Ophthotech Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$5.64
+0.23 (+4.25 %)
(As of 12/12/2019 04:00 AM ET)
Today's Range
$5.15
Now: $5.64
$5.79
50-Day Range
$1.13
MA: $1.30
$1.39
52-Week Range
$1.02
Now: $5.64
$4.50
Volume1.82 million shs
Average Volume159,109 shs
Market Capitalization$233.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$209.98 million
Book Value$3.00 per share

Profitability

Net Income$63.09 million

Miscellaneous

Employees35
Market Cap$233.61 million
Next Earnings DateN/A
OptionableOptionable

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.


Ophthotech (NASDAQ:OPHT) Frequently Asked Questions

What is Ophthotech's stock symbol?

Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech's earnings last quarter?

Ophthotech Corp (NASDAQ:OPHT) announced its earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.02. View Ophthotech's Earnings History.

Has Ophthotech been receiving favorable news coverage?

Media headlines about OPHT stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ophthotech earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Ophthotech.

Who are some of Ophthotech's key competitors?

What other stocks do shareholders of Ophthotech own?

Who are Ophthotech's key executives?

Ophthotech's management team includes the folowing people:
  • Dr. David R. Guyer, Exec. Chairman (Age 59)
  • Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)
  • Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)
  • Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)
  • Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44)

What is Ophthotech's stock price today?

One share of OPHT stock can currently be purchased for approximately $5.64.

How big of a company is Ophthotech?

Ophthotech has a market capitalization of $233.61 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. Ophthotech employs 35 workers across the globe.View Additional Information About Ophthotech.

What is Ophthotech's official website?

The official website for Ophthotech is http://www.ophthotech.com/.

How can I contact Ophthotech?

Ophthotech's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]


MarketBeat Community Rating for Ophthotech (NASDAQ OPHT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  657
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel